الفهرس 
Acute Coronary Syndrome (ACS)Only 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
ACUTE CORONARY SYNDROME (ACS) is one of the most important cardiovascular diseases that increase risk of morbidity and mortality. The primary goal in management of acute STEMI is reperfusion therapy with intravenous fibrinolysis or Primary Percutaneous Intervention (PCI). Primary PCI is also indicated as an early intervention protocol in cases of NSTEMI.
Acute kidney injury is a frequent complication among patients who undergo primary PCI. The reported incidence of Contrast Induced Nephropathy (CIN) varies widely in different populations, ranging from 7% to 25%, depending on the presence of risk factors. Hence, risk stratification is important, in order to apply the appropriate extent of prophylactic strategy in high-risk populations.
Studies have revealed many predictors for CIN after primary PCI such as red cell distribution width platelet to lymphocyte ratio, AGEF score (age, glomerular fraction, ejection fraction), one of these predictors is the CHADS VASC score. The CHADS2-VASC score has been reported as risk factors for CIN and adverse cardiac events.
The CHA2DS2-VASC (Congestive heart failure or left ventricular dysfunction, Hypertension, Age ≥75 years, Diabetes Mellitus, Previous stroke, Vascular disease, Age between (65-74) years, female gender) score was designed to determine the thromboembolic risk and oral anti-coagulant therapy in nonvalvular atrial fibrillation.
However, it was recognized to be also useful in the prediction of severity of coronary artery disease and coronary artery disease-related mortality due to the presence of some common risk factors.
SO we aimed in this study to evaluate CHA2DS2-VASC as a predictor for contrast induced nephropathy in patient with Acute Coronary Syndrome treated with percutaneous coronary intervention in order to apply the appropriate extent of prophylactic strategy in high –risk population.
This study included 130 patients presented with the acute coronary syndrome who underwent percutaneous coronary intervention at the cardiology department of Menoufia University and the national heart institute from September 2019 to May 2021.